Publications
A downloadable PDF including brief descriptions of all publications produced by the National MDS Natural History Study is available by clicking this link.
2024
DeZern A, Goll J, Jensen T, Srivatsan S, Gillis N, Abel G, Padron, E, Deeg J, Al Baghdadi T, Liu JL, Komrokji R, Gore S., Saber W, Bejar R, Walter M, Lindsley RC, Sherman S, DiFronzo N, Sekeres M; Correlation between peripheral blood and bone marrow mutations among patients with MDS from the National MDS Study. Blood Neoplasia 2024; 1 (3): 100026. doi: https://doi.org/10.1016/j.bneo.2024.100026
2023
Gorak E, Otterstatter M, Al Baghdadi T, Gillis N, Foran JM, Liu JJ, Bejar R, Gore SD, Kroft SH, Harrington AM, Saber W, Starczynowski DT, Rollison DE, Zhang L, Moscinski LC, Wilson SH, Thompson J, Borchert C, Sherman S, Hebert D, Walker ME, Padron E, DeZern A, Sekeres MA. Discordant Pathologic Diagnoses of Myelodysplastic Neoplasms and Their Implications for Registries and Therapies. Blood Adv 2023; bloodadvances.2023010061. doi: https://doi.org/10.1182/bloodadvances.2023010061
Abel GA, Hebert D, Lee C, Rollison DE, Gillis N, Komrokji RS, Foran JM, Liu JJ, Al Baghdadi T, Deeg HJ, Gore SD, Saber W, Wilson SH, Otterstatter M, Thompson J, Borchert C, Padron E, DeZern A, Cella D, Sekeres MA. Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study. Blood Adv. 2023 May 5:bloodadvances.2022009000. doi: 10.1182/bloodadvances.2022009000. Epub ahead of print. PMID: 37146263.
https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022009000/495681/Health-Related-Quality-of-Life-and-Vulnerability
DeZern AE, Goll JB, Lindsley RC, Bejar R, Wilson SH, Hebert D, Deeg HJ, Zhang L, Gore SD, Al Baghdadi T, Maciejewski JP, Liu JJ, Padron E, Komrokji RS, Saber W, Abel GA, Kroft SH, Harrington AM, Grimes T, Reed HHV, Fulton RS, DiFronzo NL, Gillis N, Sekeres MA, Walter MJ. Utility of Targeted Gene Sequencing to Differentiate Myeloid Malignancies from other Cytopenic Conditions. Blood Adv. 2023 Mar 22:bloodadvances.2022008578. doi: 10.1182/bloodadvances.2022008578. PMID: 36947201. https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2022008578/495027/Utility-of-Targeted-Gene-Sequencing-to
2022
Miller C, Walker J, Jensen T, Hopper W, Fulton R, Painter J, Sekeres M, Ley T, Spencer D, Goll J, Walter M. Failure to detect mutations in U2AF1 due to changes in the GRCh38 reference sequence. J Mol Diagn. 2022 Mar;24(3):219-223. doi: 10.1016/j.jmoldx.2021.10.013. Epub 2022 Jan 15. PMID: 35041928.
https://www.jmdjournal.org/article/S1525-1578(22)00005-8/fulltext
2019
Sekeres MA, Gore SD, Stablein DM, DiFronzo N, Abel GA, DeZern AE, Troy JD, Rollison DE, Thomas JW, Waclawiw MA, Liu JJ, Al Baghdadi T, Walter MJ, Bejar R, Gorak EJ, Starczynowski DT, Foran JM, Cerhan JR, Moscinski LC, Komrokji RS, Deeg HJ, Epling-Burnette PK. The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes. Leuk Lymphoma. 2019 Dec;60(13):3161-3171. doi: 10.1080/10428194.2019.1616186. Epub 2019 May 21. PMID: 31111762.
https://www.tandfonline.com/doi/full/10.1080/10428194.2019.1616186?scroll=top&needAccess=true
2018
Padron E, Ball MC, Teer JK, Painter JS, Yoder SJ, Zhang C, Zhang L, Moscinski LC, Rollison DE, Gore SD, Bejar R, Walter MJ, Sekeres MA, Komrokji RS, Epling-Burnette PK. Germ line tissues for optimal detection of somatic variants in myelodysplastic syndromes. Blood. 1028 May 24;131(21):2402-2405. doi:10.1182/blood-2018-01-827881 Epub 2018 Apr 16. PMID: 29661788 PMC5969383.
http://www.bloodjournal.org/content/131/21/2402.long?sso-checked=true